ArticleThorax2022
Respiratory symptoms and lung function in patients treated for pulmonary tuberculosis in Malawi: a prospective cohort study.
Article in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07067528 (The Feasibility and Acceptability of a Diagnostic Algorithm for Timely Post-tuberculosis Lung Disease Diagnosis at Primary Health Care Facilities in Mbarara, Uganda.), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Feasibility and Acceptability of a Diagnostic Algorithm for Timely Post-tuberculosis Lung Disease Diagnosis at Primary Health Care Facilities in Mbarara, Uganda.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Multimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis.BMJ global health · 2026Pooled it
- Post-pulmonary tuberculosis lung function: a systematic review and meta-analysis.The Lancet. Global health · 2025Pooled it
- Posttuberculosis Consequences on Tuberculosis Prevention Effectiveness and Cost-effectiveness among New Immigrants, Canada.Emerging infectious diseases · 2026Article
- Association between tuberculosis diagnosis delay and respiratory health and well-being among tuberculosis survivors in Cambodia: a prospective cohort study.BMJ open respiratory research · 2026Article
- Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis.American journal of respiratory and critical care medicine · 2026Article
- ITARA research programme: Investigating Integrated Tuberculosis And Respiratory care in Africa using transdisciplinary methods.BMJ open · 2026Article
- Restrictive lung function and smoking increase lung cancer risk in tuberculosis survivors: a cohort study.The Korean journal of internal medicine · 2026Article
- Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults.American journal of respiratory and critical care medicine · 2026Observational
- Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.Journal of thoracic disease · 2026Article
- Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances.Infection and immunity · 2026Review
- An integrative genetic and transcriptomic study reveals a causal link and candidate biomarkers between tuberculosis and asthma.Frontiers in genetics · 2026Article
- Pulmonary function impairment patterns and their clinical correlates in patients with pulmonary tuberculosis complicated by pulmonary infection: a single-center retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Lung function impairment in children post-tuberculosis treatment: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Review
- Inflammatory Macrophages Associate With Tissue Injury and Fibrosis in a Mouse Model of Tuberculosis.The Journal of infectious diseases · 2025Article
- Proceedings from the Third International Post-Tuberculosis Symposium: expanding the circle.IJTLD open · 2025Article
- Effect of home-based pulmonary rehabilitation on ventilation dynamics and small airway dysfunction in people with post-tuberculosis lung disease.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Lung structure and function, post-treatment, in strictly defined subclinical pulmonary tuberculosis: a prospective cohort study in Canada.ERJ open research · 2025Article
- Acceptability of pulmonary rehabilitation in Malawi: a qualitative study.BMJ open respiratory research · 2025Article
- Post-tuberculosis lung disease: towards prevention, diagnosis, and care.The Lancet. Respiratory medicine · 2025Review
- Pretreatment Chest X-ray Scores and HIV Serostatus Are Associated with Lung Function at Tuberculosis Cure.Annals of the American Thoracic Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
rationalePulmonary tuberculosis (PTB) can cause post-TB lung disease (PTLD) associated with respiratory symptoms, spirometric and radiological abnormalities. Understanding of the predictors and natural history of PTLD is limited.
objectivesTo describe the symptoms and lung function of Malawian adults up to 3 years following PTB-treatment completion, and to determine the evolution of PTLD over this period.
methodsAdults successfully completing PTB treatment in Blantyre, Malawi were followed up for 3 years and assessed using questionnaires, post-bronchodilator spirometry, 6 min walk tests, chest X-ray and high-resolution CT. Predictors of lung function at 3 years were identified by mixed effects regression modelling. MEASUREMENT AND MAIN
resultsWe recruited 405 participants of whom 301 completed 3 years follow-up (mean (SD) age 35 years (10.2); 66.6% males; 60.4% HIV-positive). At 3 years, 59/301 (19.6%) reported respiratory symptoms and 76/272 (27.9%) had abnormal spirometry. The proportions with low FVC fell from 57/285 (20.0%) at TB treatment completion to 33/272 (12.1%), while obstruction increased from and 41/285 (14.4%) to 43/272 (15.8%) at 3 years. Absolute FEV
conclusionSpirometric measures improved over the 3 years following treatment, mostly in the first year. However, a third of PTB survivors experienced ongoing respiratory symptoms and abnormal spirometry (with accelerated FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.